Tysabri belongs to a new class of humanised monoclonal antibody, known as selective adhesion molecule (SAM) inhibitors, that block
α4β1-integrin mediated leucocyte migration into infl amed tissue. It was approved by the US FDA for multiple sclerosis (MS) on 23 November 2004, at which time its name was changed from Antegren®.